2 Beaten-Down Stocks to Avoid
Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT), two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period. However, while investors are supposed to buy low, even at current levels, Editas Medicine and Sarepta aren't attractive stocks to buy.
Let's consider why investors should stay a safe distance away from these two biotech companies.
Image source: Getty Images.
Source Fool.com
Sarepta Therapeutics Stock
€18.10
-1.740%
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
Based on the current price of 18.1 € the target price of 135 € shows a potential of 646.06% for Sarepta Therapeutics which would more than double the current price.
